A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

• Safety - Treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  Treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious AEs (SAEs)
• Efficacy - PANSS total score and PANSS subscale scores (positive, negative, general psychopathology, and excitability) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  PANSS total score and PANSS subscale scores (positive, negative, general psychopathology, and excitability)
• Efficacy - Clinical Global Impression-Severity of Illness (CGI-S) score. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Clinical Global Impression-Severity of Illness (CGI-S) score.

• Physical examination [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  Physical examination
• Weight, laboratory measures, vital signs, and electrocardiograms (ECGs) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  Weight, laboratory measures, vital signs, and electrocardiograms (ECGs)
• Movement disorders, as assessed by Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BAS), and Simpson-Angus Scale (SAS) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  Movement disorders, as assessed by Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BAS), and Simpson-Angus Scale (SAS)
• Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  Columbia-Suicide Severity Rating Scale (C-SSRS)
• MADRS total score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  MADRS total score
• Short Form-12 Health Survey (SF-12) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Short Form-12 Health Survey (SF-12)
• Modified Specific Levels of Functioning (SLOF) total score and SLOF subscale scores (social functioning and community living skills) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Modified Specific Levels of Functioning (SLOF) total score and SLOF subscale scores (social functioning and community living skills)
• Brief Adherence Rating Scale (BARS) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Brief Adherence Rating Scale (BARS)
• Smoking questionnaire [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Smoking questionnaire
• Intent to Attend assessment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Intent to Attend assessment
• Euroqol (EQ-5D) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Euroqol (EQ-5D) Health Outcome measure
• Health Services Utilization Questionnaire (HSUQ) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  Health Services Utilization Questionnaire (HSUQ)- Health Outcome measure

This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.

This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia who have participated in Study D1050238, a double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia. Subjects who have completed the 28-week double-blind phase or who have experienced a protocol-defined relapse event during the double-blind phase of study D1050238 will have the option to participate in this study. In addition, if/when the study is discontinued by the sponsor, all subjects participating in the open-label phase and the double-blind phase of study D1050238 will have the option to participate in this extension study

Inclusion Criteria:

• Subject has agreed to participate by providing written informed consent.
• Subject will be eligible to participate if one of the following criteria is met:
• Subject has completed the 28-week double-blind phase of study D1050238
• Subject has experienced a protocol-defined relapse event during the double- blind phase in study D1050238
• Subject is participating in the open-label or double-blind phase of study D1050238 if/when study D1050238 is terminated by the sponsor.
• Subject has completed all required assessments on the final study visit (Study Visit Number 42) in study D1050238.
• Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.

Exclusion Criteria:

• Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
• Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at the extension baseline visit (Study Visit Number 42 in study D1050238). Subjects who answer "yes" to this question must be referred by the Investigator for appropriate follow-up evaluation and treatment.
• Subject tests positive for drugs of abuse or is suspected of current alcohol abuse at the extension baseline visit (Study Visit Number 42 in study D1050238). In the event a subject tests positive for cannabinoids, the Investigator will evaluate the subject's ability to abstain from cannabis during the study.